Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Depreciation & Amortization (CF) (2016 - 2025)

Perspective Therapeutics' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $775000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 15.84% year-over-year to $775000.0; the TTM value through Sep 2025 reached $2.9 million, up 55.29%, while the annual FY2024 figure was $2.3 million, 133.87% up from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $775000.0 at Perspective Therapeutics, up from $733000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $775000.0 in Q3 2025 and bottomed at -$78000.0 in Q4 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $255000.0 (2023), against an average of $346764.7.
  • The largest annual shift saw Depreciation & Amortization (CF) tumbled 310.81% in 2021 before it surged 240.0% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at -$78000.0 in 2021, then soared by 352.56% to $197000.0 in 2022, then soared by 53.3% to $302000.0 in 2023, then soared by 134.77% to $709000.0 in 2024, then rose by 9.31% to $775000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Depreciation & Amortization (CF) are $775000.0 (Q3 2025), $733000.0 (Q2 2025), and $732000.0 (Q1 2025).